• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[脐血来源的淋巴因子激活的杀伤细胞对裸鼠人卵巢癌模型的作用]

[Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].

作者信息

He Yue-dong, Peng Zhi-lan, Liu Shan-ling, Wang He, Pan Xiao-ling

机构信息

Department of Obsterics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Sep;38(5):810-2.

PMID:17953364
Abstract

OBJECTIVE

To explore the possibility of using lymphokine activated killer (LAK) from cord blood as an adoptive immunotherapy for ovarian cancer.

METHODS

The nude mouse models with human ovarian cancer were treated with the LAK from cord blood and compared with those treated with the LAK from the pheripheral blood.

RESULTS

The LAK from the cord blood inhibited the growth of human ovarian cancer. The average size of the tumor was 6.0 mm3 23 days after the cord blood LAK treatment, with an average weight of (0.674 +/- 0.45 g).

CONCLUSION

Cord blood can be a source of adoptive cellular immunotherapy for the treatment of ovarian cancer.

摘要

目的

探讨使用脐血来源的淋巴因子激活的杀伤细胞（LAK）作为卵巢癌过继性免疫治疗方法的可能性。

方法

用人卵巢癌裸鼠模型分别接受脐血LAK治疗和外周血LAK治疗，并进行比较。

结果

脐血LAK可抑制人卵巢癌生长。脐血LAK治疗23天后肿瘤平均体积为6.0立方毫米，平均重量为（0.674±0.45克）。

结论

脐血可作为过继性细胞免疫治疗卵巢癌的来源。

相似文献

1
[Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].[脐血来源的淋巴因子激活的杀伤细胞对裸鼠人卵巢癌模型的作用]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Sep;38(5):810-2.
2
[The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].[人LAK细胞的快速激活及其对晚期卵巢癌的抑制作用]
Zhonghua Fu Chan Ke Za Zhi. 1994 Jun;29(6):332-5, 381.
3
[Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].[淋巴因子激活的杀伤细胞对头颈肿瘤的体外及裸鼠体内作用]
Zhonghua Er Bi Yan Hou Ke Za Zhi. 1993;28(5):281-3, 314.
4
[Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells].[淋巴因子激活的杀伤细胞和白细胞介素-2对荷人卵巢癌细胞裸鼠腹水形成及存活时间的影响]
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Dec;41(12):1891-5.
5
Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.用人淋巴细胞激活的杀伤细胞和白细胞介素2对裸鼠人头颈癌异种移植瘤进行局部过继免疫治疗。
Cancer Res. 1990 May 15;50(10):3113-8.
6
Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.多种生物反应调节剂增强淋巴因子激活的杀伤细胞对卵巢肿瘤细胞的细胞毒性作用。
Anticancer Res. 1990 Mar-Apr;10(2A):441-6.
7
[Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].[淋巴因子激活的杀伤细胞（LAK细胞）的研究：在肿瘤组织中的聚集及过继性免疫治疗的疗效]
Hokkaido Igaku Zasshi. 1992 Jul;67(4):475-87.
8
[The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].YPC3单克隆抗体介导的LAK细胞在体外和体内的抗胰腺癌疗效
Zhonghua Zhong Liu Za Zhi. 1994 Sep;16(5):353-5.
9
Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.非细胞毒性和亚致死剂量的紫杉醇处理可增强培养的卵巢肿瘤SKOV-3细胞对淋巴因子激活的杀伤细胞裂解的敏感性。
Anticancer Res. 2007 Mar-Apr;27(2):841-50.
10
A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.一种使用靶向c-erbB-2和CD16的双特异性单克隆抗体进行治疗的人肿瘤异种移植模型。
Cancer Res. 1993 Jan 1;53(1):94-100.